DOCSLIB.ORG

Pap Smear Guidelines: Family Planning Update 2008 Seshu P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pap Smear Guidelines: Family Planning Update 2008 Seshu P Faculty Pap Smear Guidelines: Family Planning Update 2008 Seshu P. Sarma, MD, FAAP Part Two Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division Objectives Objectives Discuss pap smear reporting Discuss management strategies for various squamous and gladular cell Describe the Bethesda system 2006 abnormalities Discuss management of unsatisfactory smears and smears with no T zone Discuss treatment modalities for CIN component Cervical Cancer Pap Smear Reporting Pap smear screening resulted in Pap system of reporting dramatic reduction in cervical cancer − Bethesda 1988 system The value of accurate screening can be − Bethesda 1991 system reduced by loss to follow-up or under- treatment of significant lesions − Bethesda 2001 system − Bethesda 2006 system 1 Pap Reporting WHO Reporting Class 1 − Normal CIN 1 Class 2 − Mild dysplasia − Atypia, inflammation, reactive change CIN 2 Class 3 − Dysplasia − Moderate dysplasia Mild, moderate and severe CIN 3 Class 4 − Severe dysplasia − Carcinoma in situ − Carcinoma in situ Class 5 − Invasive cancer Bethesda System Bethesda 2006 146 experts Bethesda 1988 29 organizations Bethesda 2001 Met September 18-19, 2006 in Bethesda 2006 Bethesda, MD Developed revised, evidence based consensus guidelines for management of abnormal pap smears Bethesda 2006 Bethesda 2006 ASCUS Recommendations for HSIL and AGC LGSIL underwent only minor changes − Management unchanged for the above 2 categories except for More emphasis placed on immediate screen and treat for HSIL lesions adolescents − Cytologic follow-up for 2 years approved for adolescents 2 Bethesda 2006 Bethesda 2006 HPV testing was incorporated into the The 2004 interim guidance for HPV management of AGC after initial testing as a adjunct to cervical cytology evaluation with colposcopy and for screening in women 30 years of age endometrial sampling or older was formally approved Adequate Specimen Adequacy of Specimen Conventional Smear: − 8,000-12,000 well visualized cells Satisfactory specimen contains should be seen − 10 well preserved endocervical cells Liquid-based Pap: or 5,000 well visualized cells should be − 10 squamous metaplastic cells seen − − Epithelial cells may be obscured by inflammation − If >75% of cells are obscured, it is considered unsatisfactory Transformation Zone No T Zone Components Not Present • Repeat testing is recommended for • If Pap is otherwise normal, no higher women at higher risk of neoplasia risk of subsequent detection of high such as: grade SIL − Immunocompromised • Most women without an endocervical − HPV + or transformation zone component can − previous abnormal pap smears be re-screened in 12 months − Inability to visualize the cervix − Insufficient previous screening 3 Unsatisfactory Pap Smears Abnormal Pap Smears 50-60 million pap tests per year in US Pap smears that are unsatisfactory need to be repeated in 2-4 months 3.5 million are classified as abnormal and require some form of medical If three consecutive specimens are follow-up unsatisfactory, colposcopy is recommended 10,000 new cases of cervical cancer − Histologic abnormalities were found seen each year in the US in 16% of this population 4,000 deaths from cervical cancer Abnormal Pap and Inconclusive Pap Smears Cervical Cancer Almost 2 million Pap smears each year Determining which women with are classified as “inconclusive” abnormal Pap tests are at risk of significant cervical disease and treating − ASC-US, ASC-H and LSIL them presents a: Most of them have no detectable − major public health challenge problem multibillion dollar cost to our − Less than one fifth of these women healthcare system have a significant precancerous lesion Inconclusive Pap Smears Abnormal Pap Smears Effective cervical cancer prevention Although these changes are mild, they requires may result in: − Anxiety − Recognition and treatment of the precursors of invasive cancer − Unnecessary medical procedures − Extra costs to healthcare system The 2001 Bethesda System of nomenclature describes the categories of epithelial cell abnormalities seen on pap smears 4 2001 Bethesda System 2001 Bethesda System Squamous Cell: Squamous Cell: Atypical Sqaumous Cells − − High-grade squamous intraepithelial ASC-US (undetermined significance) lesions ASC-H ( can not exclude HSIL) Moderate and severe dysplasia and − Low-grade squamous intraepithelial carcinoma-in-situ (CIN II and CIN III) lesions Mild dysplasia − Squamous cell carcinoma HPV changes 2001 Bethesda System 2001 Bethesda System Glandular Cell: Glandular Cell: Atypical glandular cells − Atypical glandular cells (AGC) − Favor neoplasia Endocervical Specify endocervical Endometrial Not otherwise specified (NOS) Not otherwise specified (NOS) − Endocervical adnocarcinoma in situ (AIS) − Adenocarcinoma Precancerous Precursors HPV and Abnormal Paps CIN 2, CIN 3, adeno-carcinoma in situ The presence of HPV is a marker for the (AIS) are collectively referred to as risk of diagnosis of CIN2/3+ CIN2/3+ Only 1 in 10 to 1 in 30 HPV infections Cancer precursors include: are associated with abnormal cervical − CIN 3, AIS and to a lesser extent cytology CIN 2 Even a smaller proportion are associated with CIN2/3/+ 5 HPV HPV HPV can express as CIN within months Among women with negative cytology and a positive HPV test result, only 15% after infection will have abnormal cytology results However, the time course from CIN 3 to within 5 years invasive cancer averages between 8.1 and 12.6 years CIN Regression CIN 1 CIN 1 is the histologic appearance of Regression for CIN cells producing HPV − 60% for CIN 1 and 40% for CIN 2 The goals of cervical cancer screening: − Not to prevent CIN − But to prevent and treat Early invasive cervical cancer Reduce mortality Management of Abnormal Pap Atypical Squamous Cells Atypical Squamous Cells: Options include: − Immediate colposcopy The risk of cancer and CIN 2/3+ is low − 0.1-0.2% for cancer Provides rapid diagnosis but expensive − 6.4-11.9% for CIN2/3+ − HPV DNA testing triage − Repeat cytology at 6 and 12 months 6 HPV Testing ASCUS (HPV+) in Adolescents Hybrid Capture DNA 2 assay for 13 The risk of invasive cancer approaches zero in adolescents oncogenic HPBV sub types HPV infections are common and self Performed on the liquid based pap limiting in adolescents specimen Colposcopic evaluation is not necessary Usually done within 3 weeks of Can be monitored with pap smears at 6 obtaining the specimen and 12 months Adolescents ASCUS and LSIL in Adolescents Recommendations are similar for ASC and LSIL in adolescent girls Follow-up with cytology or HPV for up to 2 years is reasonable according to LSIL represents HPV infection and Bethesda 2006 guidelines most adolescents clear HPV and LSIL Follow-up Pap at 6 and 12 months is adequate LSIL LSIL More frequent in younger populations The risk of CIN 2/3+ at initial colposcopy following an LSIL is with larger number of recent partners between 15% and 30% Represents the appearance of cells that Colposcopy is recommended for these women are actively engaged in HPV replication For adolescents with LSIL, follow-up HPV testing is of limited value with Pap at 6 and 12 months is reasonable 7 LSIL in Adolescents LSIL in Postmenopausal Women Follow-up at 6 and 12 months Options include: − Those with HSIL need colposcopy − Reflex HPV DNA testing Follow-up at 24 months − Repeat cytology at 6 and 12 months − Those with ASCUS or greater need − Colposcopy colposcopy 2006 Bethesda guidelines Bethesda 2006 guidelines ASC-H HSIL Among women with HSIL cytology Atypical squamous cells-cannot results: exclude HSIL (ASC-H); − CIN 2 and CIN 3 have been reported − Includes 5-10% of ASC Pap smears in 70% or more cases − Invasive cancer is seen in 1-2% of − CIN2/3+ seen in 24-94% of such cases cases − Colposcopy with endocervical − Immediate colposcopic intervention evaluation should be done is necessary − Entire vagina should be examined − See and treat approach can be − HPV testing is not cost effective followed if lesion seen AGC AGC Atypical Glandular Cells: Source of the lesion − Histological correlation: − Cervix − 9-38% of women with AGC have − Endocervix significant neoplasia − Endometrium − 3-17% have cancer − CIN is the most common lesion associated with AGC 8 AGC AGC Evaluation includes: When evaluation is negative and − Colposcopy histology is negative, follow-up includes: − Endocervical curettage − AGC favor neoplasia: excision is − Endometrial sampling warranted With abnormal endometrial cells Cold knife cone is a good choice Women >35 years of age − AGC and AGC NOS Younger women with abnormal Pap and ECC every 6 months until bleeding, morbid obesity and 4 consecutive negative smears are oligomenorrhea obtained How Should CIN 1 Be CIN 2 and 3 Managed? CIN 2 and 3 are recognized potential Depends on the preferences of the cancer precursors − Physician and the patient − Although CIN2 is associated with − For most young women, observation significant spontaneous regression seems appropriate − 40% of CIN 2 cases regress over 2 − Follow-up with pap smear every 6 years months X 2 Immediate treatment of CIN2 and CIN 3 with excision or ablation is Colposcopy for an ASC or higher recommended in non-pregnant patients or a positive HPV at 12 months CIN 2 in Adolescents Management of AIS Care of the adolescent with CIN 2 may Cold-knife conization is recommended
Load more

Recommended publications
  • Family Practice
    THE JOURNAL OF FAMILY PRACTICE Michael E. Pichichero, MD Who should get Department of Microbiology and Immunology, Pediatrics, the HPV vaccine? and Medicine, University of Rochester Medical Center, Elmwood Pediatric Group, Latest recommendations from ACIP and others Rochester, NY Practice recommendations have not started sexual activity—are the • Consider recommending HPV vaccine for primary targets of immunization. How- 11- and 12-year-old girls in your practice, ever, the US Food and Drug Administra- before sexual activity puts them at risk tion also approved the use of Gardasil of viral infection (A). The FDA has also for girls as young as 9. Girls this age may approved the HPV vaccine for women require other vaccines, such as meningo- up to 26 years of age. ® Dowdencoccal conjugate Health and tetanus-diphtheria- Media acellular pertussis, and experience thus • If women older than 26 years ask to be far indicates no negative immune effects vaccinated, make sureCopyright they understandFor personalwith co-administration use only of vaccines.1,2 it is an off-label use for them (A). According to one study, vaccination Strength of recommendation (SOR) of the entire US population of 12-year-old A Good-quality patient-oriented evidence girls would prevent more than 200,000 B Inconsistent or limited-quality patient-oriented evidence C Consensus, usual practice, opinion, disease-oriented HPV infections, 100,000 abnormal Pap IN THiS ARTiCLE evidence, case series tests, and 3300 cases of cervical cancer.3 z How vaccination Parental as well as health care provider resexual adolescent girls and acceptance of HPV vaccines for adoles- prevents cervical sexually active women can now cents will be critical to the success of the cancer Plower their lifetime risk of cervical vaccination effort (see “What makes FPs Page 199 cancer, thanks to a newly available quad- recommend the HPV vaccine” on page rivalent vaccine (Gardasil) directed at hu- 201).4 z How HPV infection man papillomavirus (HPV).
    [Show full text]
  • Human Papillomavirus (HPV) and Cervical Cancer: an Update on Prevention Strategies Script August 9, 2005
    Human Papillomavirus (HPV) and Cervical Cancer: An Update on Prevention Strategies Script August 9, 2005 [1]DANIELS Hello and welcome to “Human Papillomavirus (HPV) and Cervical Cancer: An Update on Prevention Strategies.” I’m Kysa Daniels, your moderator for this program, which is originating from the Centers for Disease Control and Prevention in Atlanta, Georgia. In this Webcast, we’ll be discussing genital human papillomavirus (HPV) infection, a sexually transmitted disease. This is an extremely common infection of growing concern to both the public and to health care providers. Our focus today is - an update on the natural history of HPV infection, - the association of different HPV types with various clinical manifestations, - HPV transmission, and... - methods for HPV and cervical cancer prevention. Before we introduce our panelists, let’s hear from CDC Director, Dr. Julie Gerberding. DR. JULIE GERBERDING: Hello! I am Dr. Julie Gerberding, Director of the Centers for Disease Control and Prevention. Thanks for joining us for this very important webcast on Human Papilloma Virus. Genital infection with HPV is the most common sexually transmitted infection in the United States. About 20 million Americans are currently infected with the virus, and about 6.2 million people become newly infected each year. Most infections cause no clinical problems and go away on their own without treatment. But some infections lead to genital warts in men and women, and cervical cancer in women. Although a vaccine against HPV is in development, there is no curative treatment for genital HPV infection. Treatments are available for the abnormalities caused by HPV infection.
    [Show full text]
  • HPV and Cervical Cancer, Screening and Prevention
    HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way… Prevalence HPV in Young Adults in U.S HPV genotypes • 20% of all • 55-60% of adeno- All cancers carcinomas 16 18 The 6,11 rest • 90-95% of • 25% all warts cervical cancers HPV Vaccines • Gardisil 9: – 6, 11, 16, 18, 31, 33, 45, 52, and 58 • Gardisil: – 6, 11, 16, and 18 • Cervarix: – 16 & 18 – For girls only How Effective is the HPV vaccine? • Answer – very!!! • Large RCT of 2392 women ages 16-23 split into two groups. All women were tested for HPV virus at enrollment – One group was placebo • Rate of persistent HPV infection 3.8% – One group got series of 3 HPV 16 vaccines at 0,2,and 6 months • Rate of persistent infection 0% A controlled trial of a human papillomavirus type 16 vaccine. Koutsky LA1, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Department of Epidemiology, University of Washington, Seattle, USA. [email protected] HPV vaccine: efficacy • HPV Cancers U.S. HPV Cancers 2008-12: 38,793 – 38,793 HPV-associated cancers (11.7 per 100,000 persons) • 23,000 (13.5) among females 15,793 • 15,793 (9.7) among males. 23,000 – 30,700/38,793 = HPV attributed – 28,500/38793 = Preventable Women Men Human Papillomavirus–Associated Cancers — United States, 2008–2012 MMRW Weekly / July 8, 2016 / 65(26);661–666 74% Preventable Risk Factors Cervical Cancer Screening Being rarely or never screened is THE major contributing factor to the MOST cervical cancer deaths today.
    [Show full text]
  • Cytological Changes Preceding Cervical Cancer
    27828 Clin Pathol 1994;47:278-279 Cytological changes preceding cervical cancer J H Robertson, B Woodend, H Elliott J Clin Pathol: first published as 10.1136/jcp.47.3.278 on 1 March 1994. Downloaded from Abstract invasive disease. However, recent studies of Cervical smears were reviewed from 62 cervical intraepithelial neoplasia (CIN), the women who developed squamous carci- histological counterpart of dyskaryosis, cast noma of the cervix up to 18 years later. doubt on this concept of the evolution of The findings indicate that the prevention cancer. 1 of cervical cancer by screening depends To investigate the relation between carci- very largely on the detection of severe noma and dyskaryosis we report a study dyskaryosis. In this series there was no based on 62 women with cervical cancer, evidence that mild dyskaryosis was a describing the cytology of positive smears forerunner of invasive disease. Cytology taken up to 18 years before diagnosis of the during the evolution of squamous disease. carcinoma is not characterised by a dyskaryosis which progressively in- creases in severity. Instead the findings Methods support new concepts that cervical can- Most of these 62 patients had been given cer generally arises from an aggressive false negative smear reports by a number of CIN 3 lesion widely present in the cervix, laboratories at varying intervals before the and in our series, established years development of carcinoma. The method of before invasion occurs. It would be more tracing the patients and their smears has been useful to report cytology as showing described before.3 The present study also either a low or high grade abnormality includes patients who had positive smear rather than distinguishing between dif- reports but who were lost to follow up and ferent degrees of dyskaryosis.
    [Show full text]
  • Recommendations for Cervical Cytology Terminology
    DOI:10.1111/j.1365-2303.2007.00469.x European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology A. Herbert*, C. Bergeron , H. Wienerà, U. Schenck§, P. Klinkhamer–, J. Bulten** and M. Arbyn *GuyÕs & St ThomasÕ Hospital NHS Foundation Trust, London, UK, Laboratoire Pasteur Cerba, Cergy Pontoise, France, àInstitute of Clinical Pathology, University Vienna, Vienna, Austria, §Institute of Pathology, Technical University Munich, Munich, Germany, –PAMM, Eindhoven, The Netherlands, **Institute of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands and Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium Accepted for publication 20 April 2007 A. Herbert, C. Bergeron, H. Wiener, U. Schenck, P. Klinkhamer, J. Bulten and M. Arbyn European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology There are many different systems of cytology classification used in the member states of the European Union (EU) and many different languages. The following short annexe to Chapter 3 of the European Guidelines for Quality Assurance in Cervical Cancer Screening provides a framework that will allow different terminologies and languages to be translated into standard terminology based on the Bethesda system (TBS) for cytology while retaining the cervical intraepithelial neoplasia (CIN) classification for histology. This approach has followed extensive consultation with representatives of many countries and professional groups as well as a discussion forum published in Cytopathology (2005;16:113). This article will describe the reporting of specimen adequacy, which is dealt with in more detail elsewhere in Chapter 3 of the guidelines, the optional general categorization recommended in TBS, the interpretation ⁄ cytology result and other comments that may be made on reports such as concurrent human papillomavirus testing and the use of automation review and recommendations for management.
    [Show full text]
  • Abnormal Pap Smears: Management and Counseling
    Abnormal Pap Smears: Faculty Management and Seshu P. Sarma, M.D. Counseling Emory Regional Training Center Satellite Conference and Live Webcast Atlanta, Georgia Wednesday, February 14, 2007 2:00 - 4:00 p.m. (Central Time) Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division Program Objectives Program Objectives • Discuss the epidemiology and • Describe Bethesda 2001 Pap etiology of cervical precancerous terminology. and cancerous disease. • Describe the natural course of HPV • Discuss management guidelines for infection and its role in the development of cervical cancer. various abnormal Pap smear findings. • Discuss new Pap smear recommendations and the rationale behind the new changes. Cervical Cancer Etiology of Cervical Cancer • Incidence of Cervical Cancer: • Infection with high risk HPV – 9.2 per 100,000 (age-adjusted for the US population) in 2000 – 16,18,31,33,35,39,45,51,52,56,58,59 and 68 • Cervical cancer incidence has decreased by 77.7% from 1950 to – Mostly 16,18,45 and 31 2001 • Mortality reduced by as much as 70% – Due to pap smear screening 1 HPV Infection HPV and Cervical Cancer • The prevalence of genital HPV • HPV infections resolve infection spontaneously within 1-2 years. • Persistent infection with High Risk – Highest among sexually active HPV infection is a prerequisite for teens and women in their 20s the development of cervical cancer. • Although HPV infection is necessary – Decreases after age 30 for the development of cervical cancer, majority of women who
    [Show full text]
  • SECTIO~5.Qxd:Layout 1
    SECTION 5 Management of smear results Page Issue date 5.1 Management recommendations 1 Oct 08 5.2 Classification systems for reporting cytology 1 Oct 08 5.3 Formats in which smeartakers may receive reports 3 Oct 08 5.4 Smear result management in primary care 6 Oct 08 Appendix 5 10 Oct 08 Colposcopy Referral Form 11 Oct 08 Data Protection guidelines 12 Oct 08 References & further reading 13 Oct 08 Notes 14 CS/PUB/ST-15 Rev 2 Guide for smeartakers Management of smear results Aim of section The aim of this section is to provide an overview of the key issues relating to the management of smear results including the classification systems for reporting cytology, the management of laboratory recommendations and considerations for primary care when interpreting, communicating and recording results. 5.1 Management recommendations CervicalCheck, in consultation with laboratory specialists, has agreed recommendations for the management of the range of possible smear test results. In the national programme every eligible screening smear will carry a management recommendation. The EU recommended guidelines for best practice is a turnaround time of ten days in laboratories. 5.2 Classification systems for reporting cytology 5.2.1 Bethesda and BSCC Terminologies Smear reporting uses either the Bethesda System of Classification (TBS) or the British Society for Clinical Cytology (BSCC) CIN terminology. Bethesda terminology is used in most other countries outside of the UK and Ireland. Although the BSCC or CIN terminology has been most commonly used to date in Irish laboratories, smeartakers registered with CervicalCheck need to be familiar with both terminologies.
    [Show full text]
  • Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal Hsils
    viruses Article Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years Carmen Hidalgo-Tenorio 1,* , Juan Pasquau 1, Mohamed Omar-Mohamed 2, Antonio Sampedro 3, Miguel A. López-Ruz 1, Javier López Hidalgo 4 and Jessica Ramírez-Taboada 1 1 Infectious Disease Department, Hospital Universitario Virgen de las Nieves Granada, 18014 Granada, Spain; [email protected] (J.P.); [email protected] (M.A.L.-R.); [email protected] (J.R.-T.) 2 Infectious Disease Unit, Complejo Hospitalario Jaén, 23007 Jaén, Spain; [email protected] 3 Microbiology Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; [email protected] 4 Pathology Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +34-627010441 Abstract: Anal squamous cell carcinoma is the most frequent virus-related non-AIDS-defining neoplasia among HIV-infected individuals, especially MSM. The objectives of this study were to analyze the effectiveness of the quadrivalent HPV (qHPV) vaccine to prevent anal ≥ high-grade squamous intraepithelial lesions (≥HSILs), external ano-genital lesions (EAGLs), and infection by Citation: Hidalgo-Tenorio, C.; qHPV vaccine genotypes in HIV+ MSM, and to study the immunogenicity of the vaccine and risk Pasquau, J.; Omar-Mohamed, M.; factors for ≥ HSILs. This study is nested within a randomized, double-blind, placebo-controlled Sampedro, A.; López-Ruz, M.A.; trial of the qHPV vaccine, which enrolled participants between May 2012 and May 2014, with a López Hidalgo, J.; Ramírez-Taboada, J.
    [Show full text]
  • A Comparison of Uterine Cervical Cytology and Biopsy Results: Indications and Outcomes for Colposcopy Marian Swinker, MD, MPH; Anne C
    A Comparison of Uterine Cervical Cytology and Biopsy Results: Indications and Outcomes for Colposcopy Marian Swinker, MD, MPH; Anne C. Cutlip, MD; and Daniel Ogle, MD Morgantown, West Virginia Background. There is some debate in the literature over moderate or severe dysplasia. Of eight patients with the proper approach to the patient with a mildly ab­ atypia, 63% had dysplasia on biopsy. Of 41 patients normal cervical cytologic finding. One current ap­ with mild dysplasia on Pap smear, 37% had moderate proach for handling low-grade cytologic abnormalities dysplasia or higher grade disease on biopsy. Of nine is to perform colposcopy and biopsy if atypia, human patients with persistent inflammation on cytologic ex­ papillomavirus (HPV) changes, or mild dysplasia is amination, biopsy showed 56% with inflammation. noted on cytologic examination. If a Papanicolaou 33% with mild dysplasia, and 11% normal. (Pap) smear shows inflammation without atypia, the Conclusions. Patients who presented with minimal Pap test is repeated after 3 months, and if inflammation smear abnormalities such as HPV changes or atypia are ' does not clear, colposcopy is performed. This study likely to have a worse histologic diagnosis, with ap­ was undertaken to determine whether the above rec­ proximately two thirds showing dysplasia. Patients ommendations are appropriate. with persistent inflammation are less likely to have dys­ Methods. In a 1-year period, 125 patients underwent plasia. The results support our aggressive approach to colposcopy and biopsy. Results were reviewed and ward minimally abnormal smears and our consideration compared. of inflammation without atypia as a separate and lower1 risk category. Results. Of 47 patients with smears showing human papillomavirus (HPV) changes, 68% had a higher Key words.
    [Show full text]
  • HPV: Here, There, Everywhere Denise Rizzolo, Phd, PA-C HPV Overview
    HPV: Here, There, Everywhere Denise Rizzolo, PhD, PA-C HPV Overview • Human papillomavirus (HPV) is the most common sexually transmitted infection (STI). • According to the CDC the prevalence of genital infection with any HPV type was 42.5% among United States adults aged 18–59 years during 2013–2014. • The CDC states that HPV is so common that nearly all men and women who have sex will get it at some point in their lives. • However, many infections remain asymptomatic and resolve spontaneously. HPV Virology • Papillomavirus • Infection limited to basal cells of stratified epithelium. • Infects epithelial tissues through micro-abrasions that expose portions of the basement membrane. • HPV lesions are thought to arise from the proliferation of infected basal keratinocytes. Oncogenic Strains of HPV • 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82 • Probable oncogenic strains: 26, 53, 66, 73, 822 HPV as Causative Agent in… • Anal Cancer • Cervical Cancer • Penile Cancer • Vaginal/Vulvar Cancer • Recurrent Respiratory Papillomatosis* • *Caused most commonly by HPV types 6 + 11 (non-oncogenic) and rarely by HPV types 16/18 The History of HPV Viruses as Emerging Cause of Cancer • As early as 1842 an association was found between sexual activity and cervical cancer • By the 1990 a definitive link between HPV and cancer was determined • What about HPV and Head and Neck Cancer? • 1983 researchers found HPV structural proteins via immunohistochemistry in 6 out of 8 oral squamous cell carcinoma HPV and Oral Cancer—The stats • HPV has been detected in 45% to 90% of head and neck squamous cell carcinomas (HNSCC), most commonly in the lingual and palatine tonsils or base of the tongue.
    [Show full text]
  • Results of Cervical Cytology the 2001 Bethesda System: Terminology For
    The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology Diane Solomon; Diane Davey; Robert Kurman; et al. Online article and related content current as of February 17, 2009. JAMA. 2002;287(16):2114-2119 (doi:10.1001/jama.287.16.2114) http://jama.ama-assn.org/cgi/content/full/287/16/2114 Correction Contact me if this article is corrected. Citations This article has been cited 529 times. Contact me when this article is cited. Related Articles published in 2001 Consensus Guidelines for the Management of Women With Cervical the same issue Cytological Abnormalities Thomas C. Wright, Jr et al. JAMA. 2002;287(16):2120. New Bethesda Terminology and Evidence-Based Management Guidelines for Cervical Cytology Findings Mark H. Stoler. JAMA. 2002;287(16):2140. April 24, 2002 JAMA. 2002;287(16):2153. Subscribe Email Alerts http://jama.com/subscribe http://jamaarchives.com/alerts Permissions Reprints/E-prints [email protected] [email protected] http://pubs.ama-assn.org/misc/permissions.dtl Downloaded from www.jama.com at HSE: Health Service Executive (Ireland) on February 17, 2009 CONSENSUS STATEMENT The 2001 Bethesda System Terminology for Reporting Results of Cervical Cytology Diane Solomon, MD Objectives The Bethesda 2001 Workshop was convened to evaluate and update Diane Davey, MD the 1991 Bethesda System terminology for reporting the results of cervical cytology. A primary objective was to develop a new approach to broaden participation in the Robert Kurman, MD consensus process. Ann Moriarty, MD Participants Forum groups composed of 6 to 10 individuals were responsible for Dennis O’Connor, MD developing recommendations for discussion at the workshop.
    [Show full text]
  • The 2014 Bethesda System and Pap-Smear Soheila Aminimoghaddam1,* 1Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, IR Iran
    J Obstet Gynecol Cancer Res. 2016 August; 1(2):e7946. doi: 10.17795/ojcr-7946. Published online 2016 August 21. Letter The 2014 Bethesda System and Pap-Smear Soheila Aminimoghaddam1,* 1Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, IR Iran *Corresponding author: Soheila Aminimoghaddam, Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, IR Iran. E-mail: [email protected] Received 2016 July 19; Revised 2016 August 05; Accepted 2016 August 15. Keywords: Bethesda System, Pap Smear, Human Papilloma Virus Dear Editor, logic process. Bethesda style reporting system, such as the system c. Pregnancy-associated changes: True stromal decid- used in the cervix, is employed to report thyroid cy- ual nature of the cells in pregnancy, such as smudgy chro- topathology and pancreaticobiliary tract cytology and matin with nucleolus, can be mistaken with a high-grade urine cytology. Therefore, it is beneficial for gynecologists, squamous intraepithelial lesion. Therefore, changes asso- endocrinologists, thyroid surgeons, gastroenterologists, ciated with pregnancy should be reported as a normal pro- general surgeons, and urologists (1). cess (5). The Bethesda system (TBS) was modified in 2014, which 4. In the inflammation section, the lymphocytic (follic- altered compared to the 2001 version. According to the ular) cervicitis was added. Due to the high-prevalence of new evidence in 2014, the TBS is enhanced. The evidence in- sexually transmitted diseases, cellular changes consistent cludes an additional understanding of human papilloma with herpes simplex and cytomegalovirus were added in virus (HPV) biology, HPV vaccination in at least hundred the organism section. countries, and the high utilization of liquid base cytology 5.
    [Show full text]